The recent NEOTAX study found that responders to neoadjuvant toripalimab plus axitinib for ccRCC patients with VTT had lower densities of CD4+ T-helper cells in the tumour biopsy13. Here, CD4 is linked to nonpapillary renal cell carcinoma.